Segment Information

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

As a result of the Lake Region Medical acquisition and Spin-off, during 2016 the Company reorganized its operations including its internal management and financial reporting structure. As a result of this reorganization, the Company reevaluated and revised its reportable business segments during the fourth quarter of 2016 and began to disclose two reportable segments: (1) Medical and (2) Non-Medical. Prior period amounts have been reclassified to conform to the new segment reporting presentation. The two reportable segments, along with their related product lines, are described below:

Medical - includes the (i) Cardio & Vascular product line, which includes introducers, steerable sheaths, guidewires, catheters, and stimulation therapy components, subassemblies and finished devices that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery; (ii) Cardiac & Neuromodulation product line, which includes batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices; and (iii) Advanced Surgical, Orthopedics & Portable Medical product line, which includes components, sub-assemblies, finished devices, implants, instruments and delivery systems for a range of surgical technologies to the advanced surgical market, including laparoscopy, orthopedics and general surgery, biopsy and drug delivery, joint preservation and reconstruction, arthroscopy, and engineered tubing solutions. Products also include life-saving and life-enhancing applications comprising of automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools.

Non-Medical - includes primary (lithium) cells, and primary and secondary battery packs for applications in the energy, military and environmental markets.

During the first quarter of 2017, the Company revised the method used to present sales by product line in order to align the legacy Greatbatch and Lake Region Medical methodologies.  The Company believes the revised presentation will provide improved reporting and better transparency into the operational results of its business and markets.  Prior period amounts have been reclassified to conform to the new product line sales reporting presentation.

The tables below present information about our reportable segments (in thousands):

	Three Months Ended
	March 31, 2017		April 1, 2016
Segment sales by product line:
Medical
Cardio & Vascular	$	125,108	$	113,671
Cardiac & Neuromodulation	103,813		108,533
Advanced Surgical, Orthopedics & Portable Medical	105,146		98,362
Total Medical	$	334,067	$	320,566
Non-Medical	11,346		11,672
Total sales	$	345,413	$	332,238

(15.)BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued)

There were no sales between segments during the three months ended March 31, 2017 and April 1, 2016.

	Three Months Ended
	March 31, 2017			April 1, 2016
Segment income (loss) from operations:
Medical	$	50,360		$	31,841
Non-Medical	1,562			(1,011		)
Total segment income from operations	51,922			30,830
Unallocated operating expenses	(25,377		)	(19,696		)
Operating income	26,545			11,134
Unallocated expenses, net	(30,740		)	(23,896		)
Loss before provision (benefit) for income taxes	$	(4,195	)	$	(12,762	)